More Pegbio Co., Ltd. Class H news Pegbio Co., Ltd. Class HHKEX: 2565 Voluntary announcement core product visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment Jun 29, 2026 at 10:25 AM UTC · Issued by Pegbio Co., Ltd. Class H via HKEXnews As issuedPlain English Pegbio Co., Ltd. Class H (2565) Press ReleaseView Attachment Company analysis Earlier from Pegbio Co., Ltd. Class HNext Day Disclosure ReturnJun 26List of directors and their roles and functionsJun 24All Pegbio Co., Ltd. Class H news releases↗
